Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia

Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making

(2020) Simona Soverini et al.   BLOOD

Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α

(2020) Raquel Alves et al.   Journal of Translational Medicine

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

(2020) A. Hochhaus et al.   LEUKEMIA

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

(2020) Shinya Kimura et al.   Lancet Haematology

Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

(2020) Jonathan Cohen et al.   LEUKEMIA & LYMPHOMA

Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides

(2020) Hao Yang et al.   CANCER LETTERS

Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission

(2020) Philippe Rousselot et al.   Blood Advances

Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection

(2020) Lorena Vigón et al.   BIOCHEMICAL PHARMACOLOGY

First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?

(2020) Vivian G. Oehler   Hematology-American Society of Hematology Education Program

The New ELN Recommendations for Treating CML

(2020) Rüdiger Hehlmann   Journal of Clinical Medicine

The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

(2019) Michele Baccarani et al.   LEUKEMIA

Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry

(2019) Anna Lübking et al.   BONE MARROW TRANSPLANTATION

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges

(2019) Simona Soverini et al.   Journal of Hematology & Oncology

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome

(2019) Marc G. Berger et al.   BRITISH JOURNAL OF HAEMATOLOGY

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

(2019) Richard E Clark et al.   Lancet Haematology

Dasatinib protects humanized mice from acute HIV-1 infection

(2019) María Salgado et al.   BIOCHEMICAL PHARMACOLOGY

Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt)

(2019) Koji Nagafuji et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

(2019) Gabriele Gugliotta et al.   BLOOD

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

(2019) Timothy P. Hughes et al.   BLOOD

Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

(2019) Neil P. Shah et al.   LEUKEMIA & LYMPHOMA

Epidemiologic Signatures in Cancer

(2019) H. Gilbert Welch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice

(2019) Richard E. Clark   Current Hematologic Malignancy Reports

Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection

(2019) Núria Climent et al.   Frontiers in Pharmacology

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

(2019) Simona Soverini et al.   BLOOD

Role of cancer immunology in chronic myelogenous leukemia

(2019) Hiroshi Ureshino et al.   LEUKEMIA RESEARCH

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

(2018) François-Xavier Mahon et al.   ANNALS OF INTERNAL MEDICINE

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial

(2018) Jorge E. Cortes et al.   BLOOD

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease

(2018) Susan Branford et al.   BLOOD

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

(2018) Masaya Okada et al.   Clinical Lymphoma Myeloma & Leukemia

Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan

(2018) Naoto Takahashi et al.   HAEMATOLOGICA

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

(2018) David M. Ross et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

(2018) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

(2018) Susanne Saussele et al.   LANCET ONCOLOGY

Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan

(2018) Naoto Takahashi et al.   HAEMATOLOGICA

Development, function and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia

(2018) Sabrina Inselmann et al.   CANCER RESEARCH

Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors

(2018) Jorge Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

(2018) David M. Ross et al.   LEUKEMIA

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

(2017) Delphine Rea et al.   HAEMATOLOGICA

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study

(2017) Naoto Takahashi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia

(2017) Sieghart Sopper et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

(2017) Gabriel Etienne et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

(2017) C Schütz et al.   LEUKEMIA

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

(2017) A Hochhaus et al.   LEUKEMIA

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

(2017) R Hehlmann et al.   LEUKEMIA

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

(2017) Andreas Hochhaus et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic immune monitoring of CD4+CD25+ T cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

(2017) Ziyuan Lu et al.   Oncology Letters

CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients

(2017) M Matsushita et al.   Blood Cancer Journal

Cytomegalovirus pulls strings behind NK cells

(2017) Norimitsu Kadowaki et al.   Oncotarget

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

(2017) Delphine Rea et al.   HAEMATOLOGICA

Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission

(2017) Amy Hughes et al.   Frontiers in Immunology

Ponatinib: A Review of Efficacy and Safety

(2017) Fulvio Massaro et al.   CURRENT CANCER DRUG TARGETS

Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers

(2016) Patrick Carlier et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

(2016) Delphine Rea et al.   BLOOD

Moving treatment-free remission into mainstream clinical practice in CML

(2016) Timothy P. Hughes et al.   BLOOD

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

(2016) Charles A. Schiffer et al.   CANCER

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

(2016) S.-E. Lee et al.   HAEMATOLOGICA

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

(2016) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

(2016) Hannah Bower et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

(2016) H Hjorth-Hansen et al.   LEUKEMIA

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

(2016) M Ilander et al.   LEUKEMIA

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

(2016) A Hochhaus et al.   LEUKEMIA

The concept of treatment-free remission in chronic myeloid leukemia

(2016) S Saußele et al.   LEUKEMIA

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

(2016) J L Steegmann et al.   LEUKEMIA

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

(2016) S.-E. Lee et al.   HAEMATOLOGICA

Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

(2015) Silvia Mori et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pediatric chronic myeloid leukemia is a unique disease that requires a different approach

(2015) N. Hijiya et al.   BLOOD

Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012

(2015) Noortje Thielen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

(2015) A Gratwohl et al.   LEUKEMIA

Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells

(2015) C Riether et al.   LEUKEMIA

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

(2015) M Pfirrmann et al.   LEUKEMIA

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

(2015) L Kalmanti et al.   LEUKEMIA

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

(2015) N C P Cross et al.   LEUKEMIA

Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML.

(2015) Umit Malkan   UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

(2015) Koji Sasaki et al.   Lancet Haematology

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

(2015) Jun Imagawa et al.   Lancet Haematology

Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation

(2014) V. D. Kheav et al.   HAEMATOLOGICA

Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?

(2014) Johan Richter et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors

(2014) N. Larmonier et al.   JOURNAL OF IMMUNOLOGY

Clinical use of dendritic cells for cancer therapy

(2014) Sébastien Anguille et al.   LANCET ONCOLOGY

Inhibition of c-Kit signaling is associated with reduced heat and cold pain sensitivity in humans

(2014) Marta Ceko et al.   PAIN

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

(2013) M. L. Green et al.   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML

(2013) S Ito et al.   BONE MARROW TRANSPLANTATION

Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib

(2013) Izuru Mizoguchi et al.   CANCER SCIENCE

NK cell-based immunotherapy for malignant diseases

(2013) Min Cheng et al.   Cellular & Molecular Immunology

Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

(2013) Iwona Hus et al.   FOLIA HISTOCHEMICA ET CYTOBIOLOGICA

Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients

(2013) Asmaa M. Zahran et al.   International Journal of Clinical Oncology

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

(2013) Philippe Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia

(2013) W Scheper et al.   LEUKEMIA

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

(2013) Lisa Christiansson et al.   PLoS One

Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients

(2012) Alexis Rossignol et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

(2012) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

(2012) S Mustjoki et al.   LEUKEMIA

Standardized definitions of molecular response in chronic myeloid leukemia

(2012) N C P Cross et al.   LEUKEMIA

Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

(2011) B. Simonsson et al.   BLOOD

Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients

(2011) A. H. Elmaagacli et al.   BLOOD

Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia

(2011) M. Bornhauser et al.   BLOOD

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function

(2011) B. Foley et al.   BLOOD

Quantitative and functional analyses of CD4+CD25+FoxP3+ regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate

(2011) Emmanuel Bachy et al.   BRITISH JOURNAL OF HAEMATOLOGY

Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib

(2011) Kazuma Ohyashiki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Graft-versus-Leukemia (GVL) against Mouse Blast-Crisis Chronic Myelogenous Leukemia (BC-CML) and Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Shared Mechanisms of T Cell Killing, but Programmed Death Ligands Render CP-CML and Not BC-CML GVL Resistant

(2011) C. Matte-Martone et al.   JOURNAL OF IMMUNOLOGY

Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia

(2011) Haruko Shima et al.   JOURNAL OF PEDIATRICS

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice

(2011) C I-U Chen et al.   LEUKEMIA

Imatinib has adverse effect on growth in children with chronic myeloid leukemia

(2011) Deepak Bansal et al.   PEDIATRIC BLOOD & CANCER

Natural Killer Cell Mediated Missing-Self Recognition Can Protect Mice from Primary Chronic Myeloid Leukemia In Vivo

(2011) Mika Kijima et al.   PLoS One

Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease

(2011) A. Hochhaus   Hematology-American Society of Hematology Education Program

NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies

(2010) G. Magri et al.   BLOOD

Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive

(2010) Jose M. Rojas et al.   EXPERIMENTAL HEMATOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Immunogenic antigens as therapeutic targets against myeloid leukaemic cells

(2010) Susanne Hofmann et al.   LEUKEMIA RESEARCH

Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia

(2010) Deepika Kanojia et al.   LEUKEMIA RESEARCH

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Donor and Recipient CMV Serostatus and Outcome of Pediatric Allogeneic HSCT for Acute Leukemia in the Era of CMV-Preemptive Therapy

(2009) Carolyn E. Behrendt et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment

(2009) G. Riva et al.   BLOOD

Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression

(2009) S. Mumprecht et al.   BLOOD

Natural Killer Cell IFN-  Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients

(2009) C. Menard et al.   CANCER RESEARCH

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia

(2008) C. Quintarelli et al.   BLOOD

Aurora-A kinase: a novel target of cellular immunotherapy for leukemia

(2008) T. Ochi et al.   BLOOD

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

(2008) S. Branford et al.   BLOOD

Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update

(2008) R. Seggewiss et al.   CYTOTHERAPY